Living with myelofibrosis and anemia means dealing with low red blood cell counts, which can drain energy and disrupt daily life. Patients often face a difficult choice: stick with a treatment that manages symptoms but does not fix the anemia, or switch to something new that might work better. The pace of research in this area has accelerated, bringing more therapies to the market. However, this abundance of options creates a new challenge for patients and doctors. The central question is no longer whether treatments exist, but how to select the right one for a specific patient profile.
Goals of Modern Therapy
Doctors focus on improving symptoms for those with myelofibrosis, including anemia. A haematologist in Boston noted that for patients with anemia, the priority is to resolve the condition. Patients also want to reduce or eliminate the need for blood transfusions and ease chronic fatigue. The prospect of becoming transfusion-dependent adds significant anxiety to the disease burden, according to a 2025 study. The research found that both current and prospective patients fear the logistical and emotional challenges of regular transfusions.
Guidelines from the National Comprehensive Cancer Network recommend evaluating a patient for potential stem cell transplant if they have high-risk disease. This procedure is the only potentially curative option available today. For those with lower-risk or early-stage disease, doctors often consider other approaches. The challenge remains knowing where to start when the first therapy does not improve anemia as hoped.
Specific Anemia Treatments
Luspatercept is an injection given under the skin every three weeks to help immature blood cells mature. Erythropoiesis-stimulating agents, or ESAs, are lab-made versions of a natural hormone that stimulates red blood cell production. These injections are often given once a week or up to every three weeks. Epoetin alfa is typically given subcutaneously once a week. Darbepoetin alfa is a longer-acting option that may begin at a weekly dose and be extended to once every two to three weeks.
JAK Inhibitors and Other Options
Janus kinase inhibitors are the most common treatment for symptomatic myelofibrosis. Four drugs in this category are approved by the U.S. Food and Drug Administration: ruxolitinib, pacritinib, fedratinib, and momelotinib. The choice of drug often depends on symptoms and platelet counts. Ruxolitinib, the first approved JAK inhibitor, is taken orally and is available in an extended-release form. Anemia is a known side effect of many JAK inhibitors, though some patients see their blood counts improve while on them.
When anemia develops on a current JAK inhibitor, doctors may add a separate medication or switch to momelotinib, which was approved specifically for myelofibrosis with anemia. Other treatments include interferons, such as ropeginterferon alfa-2b, which can help modify the disease and slow progression. Hydroxyurea, a decades-old chemotherapy drug, is still a common first-line treatment but can worsen anemia. For patients who cannot tolerate standard options, allogeneic hematopoietic cell transplant remains a possibility for those with high-risk disease.
Specialists emphasize that patients should not simply accept a treatment that is not working. If anemia persists despite symptom relief, switching to another medication may provide better outcomes. This approach allows for a more personalized strategy, targeting the specific needs of the patient’s blood counts and overall health. The increasing availability of these targeted therapies means that clinicians have more tools to tailor treatment plans to individual cases.
Addressing Anemia Directly
Research is also looking at new therapies that will not cause anemia or may improve it. Clinical trials are exploring combination therapies that add anemia medications to established myelofibrosis treatments. However, handling these choices requires guidance from a specialist familiar with myeloproliferative neoplasms. The goal is to match the right therapy to the right patient, balancing symptom control with the specific needs of their blood count profile.
Stem Cell Transplant Considerations
An allogeneic hematopoietic cell transplant remains the only potentially curative treatment for myelofibrosis today. This procedure involves a donor-assisted stem cell or bone marrow transplant. Doctors may consider this option for individuals with high-risk disease or when other treatments have not been effective. However, this is a high-risk procedure. A person must meet specific health criteria to achieve the most positive outcome. Clinical guidelines recommend that every person with high-risk myelofibrosis receive an evaluation for potential transplant. The decision to proceed with the surgery is ultimately the patient’s choice.
